Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation

Bone Marrow Transplantation volume 47, pages 24–32 (2012)Cite this article

Abstract

Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ⩽70 × 109/L (n=48); group B, those having a CD34+ cell peak between 70 and 183 × 109/L (n=24); group C, those having a CD34+ cell peak >183 × 109/L (n=24). Irrespective of post-remission treatment received, group A had a disease free survival (DFS) of 73%, group B a DFS of 51% and group C of 30% (P=0.0003). In intermediate cytogenetic risk patients, those treated by autologous transplantation had a DFS of 68, 33 and 14% in the groups A, B and C, respectively, (P=0.01) whereas after allogeneic transplantation DFS was 87% in group A+B vs 50% in group C (P=0.009). The peak of CD34+ cells in PB, was an independent predictor for DFS in multivariate analysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Keating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A et al. The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003; 17: 60–67.

    Article  CAS  PubMed  Google Scholar 

  2. Feller N, Schuurhuis GJ, van der Pol MA, Westra G, Weijers GW, van Stijn A et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68–75.

    Article  CAS  PubMed  Google Scholar 

  3. Moog R . Mobilization and harvesting of peripheral blood stem cells. Curr Stem Cell Res Ther 2006; 1: 189–201.

    Article  CAS  PubMed  Google Scholar 

  4. Lee J, Lee MH, Park KW, Kang JH, Im DH, Kim K et al. Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission. Int J Hematol 2005; 81: 258–263.

    Article  PubMed  Google Scholar 

  5. Carral A, de la Rubia J, Martỳn G, Mollá S, Martỳnez J, Sanz GF et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003; 27: 5–12.

    Article  CAS  PubMed  Google Scholar 

  6. Pastore D, Specchia G, Mestice M, Liso A, Pannunzio A, Carluccio P et al. Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells. Bone Marrow Transplant 2004; 33: 1083–1087.

    Article  CAS  PubMed  Google Scholar 

  7. Barnett D, Janossy G, Lubenko A, Matutes E, Newland A, Reilly JT . Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Clin Lab Haem 1999; 21: 301–308.

    Article  CAS  Google Scholar 

  8. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone A et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354–365.

    Article  CAS  PubMed  Google Scholar 

  9. Bacigalupo A, Ballen B, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Milone G, Coppoletta S, Battiato K, Murgano P, Pinto V, Poidomani M . In normal donors bone marrow harvests can result in a CD34+ contents and in a neutrophil engraftment time equivalent to that obtained using PBSC mobilization and PBSC collections. Bone Marrow Transplant 2007; 39: S1, abstract 612.

    Article  Google Scholar 

  11. Bug G, Atta J, Klein SA, Hertenstein B, Bergmann L, Boehrer S et al. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Annal Hematol 2005; 84: 748–754.

    Article  CAS  Google Scholar 

  12. Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F . Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34 cells from leukapheresis products autografted during the first remission. Blood 2010; 116: 3157–3162.

    Article  CAS  PubMed  Google Scholar 

  13. Stelljes M, van Biezen A, Slavin S, Olavarria E, Clark RE, Nagler A et al. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2008; 42: 739–742.

    Article  CAS  PubMed  Google Scholar 

  14. Jung A, Holman P, Castro J, Carrier E, Bashey A, Lane T et al. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biol Blood Marrow Transplant 2009; 15: 1306–1313.

    Article  CAS  PubMed  Google Scholar 

  15. Novitzky N, Thomas V, du Toit C, McDonald A . Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? a retrospective analysis. Biol Blood Marrow Transplant (e-pub ahead of print 27 September 2010; doi:10.1016/j.bbmt.2010.09.016).

    Article  PubMed  Google Scholar 

  16. Lemoli RM, D’Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M et al. BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study. Bone Marrow Transplant 2010; 45: 640–646.

    Article  CAS  PubMed  Google Scholar 

  17. Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944–4951.

    Article  PubMed  Google Scholar 

  18. Nakasone H, Izutsu K, Wakita S, Yamaguchi H, Muramatsu-Kida M, Usuki K . Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. Biol Blood Marrow Transplant 2008; 14: 1262–1269.

    Article  CAS  PubMed  Google Scholar 

  19. Locatelli F, Labopin M, Ortega J, Meloni G, Dini G, Messina C et al. Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. Blood 2003; 101: 1611–1619.

    Article  CAS  PubMed  Google Scholar 

  20. Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2004; 89: 1238–1247.

    PubMed  Google Scholar 

  21. Martino R, Kerguelen A, Valcarcel D, Sureda A, Fachini L, Pinana JP et al. Reduction of infection-related mortality after allogeneic PBSCTfrom HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. Bone Marrow Transplant 2011; 46: 690–701.

    Article  CAS  PubMed  Google Scholar 

  22. Cornelissen JJ, van Putten W, Verdonck L, Theobald M, Jacky E, Daenen S et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658–3666.

    Article  CAS  PubMed  Google Scholar 

  23. Jacobsohn DA, Tse WT, Chaleff S, Rademaker A, Duerst R, Olszewski M et al. High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 2009; 146: 669–674.

    Article  CAS  PubMed  Google Scholar 

  24. Mrozek K, Marcucci G, Paschka P, Whitman S, Clara D . Bloomfield. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109: 431–448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Marcucci G . Molecular prognostic factors in ‘Therapy for Acute Myeloid Leukema: what therapy and when?’ Symposium report. Blood Marrow Transplant Rev 2010; 20: 5–7.

    Google Scholar 

  26. Milone G, Avola G, Farsaci B, Leotta S, Strano A, Camuglia MG et al. Chemo-sensitivity of clonogenic marrow precursors in AML patients in complete remission: association with CD34+ mobilization and with disease-free survival. Exp Hematol 2009 (submitted).

  27. Ragusa M, Avola G, Angelica R, Barbagallo D, Guglielmino MR, Duro L et al. Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer 2010; 10: 377–390.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Bendall LJ, Daniel A, Kortlepel K, Gottlieb DJ . Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol 1994; 13: 1252–1260.

    Google Scholar 

Download references

Acknowledgements

This study is partially funded by Progetto Obiettivo Ricerca Regione Sicilia (Italy) and by Fondazione Fon.ca.ne.sa.-Catania (Italy); we are grateful to Dr Giovanni Tripepi from the Institute of Clinical Epidemiology-CNR-Reggio Calabria (Italy) for helpful discussion and advices in performing multivariate analysis. English version revised by BioMed Proofreading (Ohio-USA).

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Unit, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy

    G Milone, M Poidomani, S Leotta, G Avola, M G Camuglia, A Privitera, C Consoli, S Mercurio, M A Romeo, A Di Marco, S Di Mercurio, A Spadaro, G A Palumbo & P Tedeschi

Authors
  1. G Milone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Poidomani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Leotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Avola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M G Camuglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Privitera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Consoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Mercurio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M A Romeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Di Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Di Mercurio
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Spadaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G A Palumbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Tedeschi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Milone.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milone, G., Poidomani, M., Leotta, S. et al. Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation. Bone Marrow Transplant 47, 24–32 (2012). https://doi.org/10.1038/bmt.2011.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.33

Keywords

Search

Advanced search

Quick links